Provided by Tiger Trade Technology Pte. Ltd.

Skye Bioscience Inc.

2.17
-0.0700-3.13%
Post-market: 2.170.00000.00%19:53 EDT
Volume:162.27K
Turnover:343.44K
Market Cap:9.53M
PE:-0.21
High:2.32
Open:2.26
Low:1.97
Close:2.24
52wk High:39.92
52wk Low:1.97
Shares:4.39M
Float Shares:2.87M
Volume Ratio:0.05
T/O Rate:5.66%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-10.2399
EPS(LYR):-11.2801
ROE:-233.87%
ROA:-95.06%
PB:-19.16
PE(LYR):-0.19

Loading ...

Skye Bioscience - Enters $22 Mln Securities Purchase Agreement with Redmile Biopharma Investments Iii - SEC Filing

THOMSON REUTERS
·
7 hours ago

Skye Bioscience Enters up to USD 22 Million Equity Line with Redmile Affiliate in Unregistered Share Sale

Reuters
·
7 hours ago

NASDAQ Trade Halt Continues Halt News Pending at 03:28 Am

Reuters
·
Aug 23

Skye Bioscience Inc trading halted, news pending

TIPRANKS
·
Aug 22

5AM Partners VII Disposes of 375,840 Skye Bioscience Shares Worth $134,482.80

Reuters
·
Aug 21

Skye Bio Amends 8-K to Set Aug. 24 Effective Date for Reverse Stock Split

Reuters
·
Aug 20

Skye Bioscience Flags NASDAQ Noncompliance After Stockholders’ Equity Falls to ($497,307)

Reuters
·
Aug 19

Skye Bioscience Inc trading halted, news pending

TIPRANKS
·
Aug 16

NASDAQ Trade Halt Volatility Trading Pause at 10:00 Am

Reuters
·
Aug 14

Skye Bioscience: Qtrly EPS $-0.27 - SEC Filing

THOMSON REUTERS
·
Aug 14

Skye Bioscience Q2 2026 Operating Loss Narrows 39.37% to $11.06 Million

Reuters
·
Aug 14

Skye Bioscience to Acquire Redx Pharma, Rebrand as Fibrx Therapeutics on NASDAQ

Reuters
·
Aug 14

Skye Bioscience - Redx Enters Series a Financing Agreement for $36 Mln

THOMSON REUTERS
·
Aug 14

Skye Bioscience and Redx Pharma Announce Transaction Agreement and $125 Million in Financings

THOMSON REUTERS
·
Aug 14

Skye Bioscience - Holders to Receive CVR for 90% of Nimacimab Net Proceeds for 12 Months Post-Closing

THOMSON REUTERS
·
Aug 14

Skye Bioscience - Combined Company Cash Expected to Fund Operations into 2029 and Rxc008 Phase 2 Data in H2 2028

THOMSON REUTERS
·
Aug 14

Skye Bioscience - Post Deal Skye to Own 5.38% of Combined Co with Holding Redx 46.17%, Financing Investors 48.45%

THOMSON REUTERS
·
Aug 14

Skye Bioscience - Peter Collum to Serve as CFO of Fibrx Therapeutics

THOMSON REUTERS
·
Aug 14

Skye Bioscience - Combined Company to Operate as Fibrx Therapeutics and Trade on NASDAQ

THOMSON REUTERS
·
Aug 14

Skye Bioscience - to Buy Entire Issued Share Capital of Redx

THOMSON REUTERS
·
Aug 14